SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design

/in ,

SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design